Unknown

Dataset Information

0

Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

ABSTRACT:

SUBMITTER: Adderley H 

PROVIDER: S-EPMC6976499 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Erlotinib plus bevacizumab for <i>EGFR</i>-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

Adderley Helen H   Ackermann Christoph Jakob CJ   Califano Raffaele R  

Annals of translational medicine 20191201 Suppl 8

Similar Datasets

Unknown Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC6692685 | biostudies-literature
Unknown Bevacizumab Plus EGFR-TKIs vs EGFR-TKIs Alone for Advanced EGFR-Mutant NSCLC: A Meta-Analysis.
| S-EPMC12824130 | biostudies-literature
Unknown First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.
| S-EPMC10413910 | biostudies-literature
Unknown Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer.
| S-EPMC12770627 | biostudies-literature
Unknown First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.
| S-EPMC11520869 | biostudies-literature
Unknown Erlotinib plus bevacizumab versus erlotinib alone in patients with <i>EGFR</i>-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.
| S-EPMC9396158 | biostudies-literature
Unknown Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring <i>EGFR</i> mutations.
| S-EPMC7867760 | biostudies-literature
Unknown Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
| S-EPMC4134127 | biostudies-literature
Unknown Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.
| S-EPMC12541177 | biostudies-literature
Unknown Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
| S-EPMC3896238 | biostudies-literature